Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10344666 | 0.75 | ESR1 (0.44) | CYP2D6SRCTSHRLMNA | |
| SCHEMBL27672496 | 0.75 | CHRNA7 (0.44) | LMNACES2CES1 | |
| SCHEMBL28247246 | 0.75 | HDAC4 (0.46) | CES2CES1 | |
| SCHEMBL11234754 | 0.74 | MIF (0.41) | CYP2D6SRCDPP4TSHRF2 | |
| SCHEMBL27609874 | 0.74 | TSHR (0.38) | CYP2D6SRCDPP4TSHRF2 | |
| SCHEMBL1323137 | 0.74 | TSHR (0.52) | DPP4TSHRF2LMNATRPA1 | |
| SCHEMBL10159567 | 0.74 | TSHR (0.52) | DPP4TSHRF2LMNATRPA1 | |
| SCHEMBL11317567 | 0.74 | MIF (0.41) | CYP2D6SRCDPP4TSHRF2 | |
| SCHEMBL11615117 | 0.73 | CFTR (0.48) | TSHRLMNA | |
| SCHEMBL9795464 | 0.72 | SRC (0.42) | CYP2D6SRCDPP4TSHRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | claimed |
| US-4388310-A | ANTIBIOTIC | MERCK & CO., INC. (US) | 1983-06-14 | — | — | US | claimed |
| US-4298741-A | DETHIAPENICILLIN ANTIBIOTICS | MERCK & CO., INC. (US) | 1981-11-03 | — | — | US | claimed |
| US-4277482-A | AMINO ACID DERIVATIVE ANTIBIOTICS | MERCK & CO., INC. (US) | 1981-07-07 | — | — | US | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4255423-A | BACTERICIDES | MERCK & CO., INC. (US) | 1981-03-10 | — | — | US | claimed |
| US-4224336-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-09-23 | — | — | US | claimed |
| US-4215124-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-07-29 | — | — | US | claimed |
| EP-0002210-A1 | 6- and 6,6- disubstituted-2-substituted-pen-2-em-3-carboxylic acids; processes for their preparation and pharmaceutical compositions containing such compounds | MERCK & CO. INC. (US) | 1979-06-13 | — | — | EP | claimed |
| US-4086423-A | CEPHALOSPORINS, CYCLOADDITION OF GLYCINE DERIVATIVE TO THIAZINE COMPOUND | MERCK & CO., INC. (US) | 1978-04-25 | — | — | US | claimed |
| CN-107502412-A | A kind of high temperature resistant type magnesium salts detergent for lubricating oil and preparation method thereof | 黄山学院 | 2017-12-22 | — | — | CN | disclosed |
| CN-105392363-B | Sample Fixation and Stabilization | A·S·戈尔兹伯勒 | 2017-09-29 | — | — | CN | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-3979384-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3974151-A | Cephalosporin compounds | MERCK & CO., INC. (US) | 1976-08-10 | — | — | US | disclosed |
| US-3962231-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | CYP2D6 3447/4885SRC 3819/4885DPP4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.